M-A: Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens – The pooled prevalence of co-infection at the time of a SARS-CoV-2 diagnosis was 19%, and that of superinfection was 24%.
Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis – PLOS One
The post M-A: Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens – The pooled prevalence of co-infection at the time of a SARS-CoV-2 diagnosis was 19%, and that of superinfection was 24%. appeared first on Links Medicus.
Report: Face masks effectively limit the probability of SARS-CoV-2 transmission.
Face masks effectively limit the probability of SARS-CoV-2 transmission – Science
The post Report: Face masks effectively limit the probability of SARS-CoV-2 transmission. appeared first on Links Medicus.
Perspective | Tracking lives we’ve lost to COVID-19.
Tracking Lives We’ve Lost to COVID-19 – Think Global Health Related: COVID-19 has caused 6.9 million deaths globally, more than double what official reports show
The post Perspective | Tracking lives we’ve lost to COVID-19. appeared first on Links Medicus.
Covid-19 pandemic: approximately one million excess deaths occurred in 2020 in 29 high income countries.
Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries – The BMJ Editorial: Measuring the impact of covid-19 Commentary: Nearly 1 million excess deaths in 29 nations during pandemic – CIDRAP Related: COVID-19 has caused 6.9 million deaths globally, more than double what official […]
The post Covid-19 pandemic: approximately one million excess deaths occurred in 2020 in 29 high income countries. appeared first on Links Medicus.
Observational study finds a single dose of either Pfizer-BioNTech and Oxford-AstraZeneca vaccines in older adults is about 80% effective at preventing admission to hospital with covid-19.
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study – The BMJ Editorial: Effectiveness of England’s initial vaccine roll out – The BMJ
The post Observational study finds a single dose of either Pfizer-BioNTech and Oxford-AstraZeneca vaccines in older adults is about 80% effective at preventing admission to hospital with covid-19. appeared first on Links Medicus.
ERS clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years.
European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years – European Respiratory Journal
The post ERS clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years. appeared first on Links Medicus.
Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection
Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection – JAMA Network Open Editorial: The Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2 Infection—Another Piece of an Expanding Puzzle Commentary: COVID-related inflammatory syndrome looks different in adults – CIDRAP
The post Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection appeared first on Links Medicus.
Systematic review and meta-analysis of observational studies suggest low-dose aspirin may be of benefit for patients with Covid-19 – the finds require further investigation in randomized studies.
Active Prescription of Low-dose Aspirin During or Prior to Hospitalization and Mortality in COVID-19 — A Systematic Review and Meta-analysis of Adjusted Effect Estimates – International Journal of Infectious Diseases
The post Systematic review and meta-analysis of observational studies suggest low-dose aspirin may be of benefit for patients with Covid-19 – the finds require further investigation in randomized studies. appeared first on Links Medicus.
FDA In Brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination.
FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to Evaluate Immunity or Protection From COVID-19, Including After Vaccination – U.S. Food & Drug Administration Commentary on Twitter (thread – click for more) Today, we issued a safety communication notifying the public and providers that results from SARS-CoV-2 antibody tests should […]
The post FDA In Brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination. appeared first on Links Medicus.
One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively
Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study – Lung
The post One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively appeared first on Links Medicus.